АНАЛИЗ ПОКАЗАТЕЛЕЙ ВЫЖИВАЕМОСТИ БОЛЬНЫХ ГЕМОБЛАСТОЗАМИ В САНКТ -ПЕТЕРБУРГЕ НА ПОПУЛЯЦИОННОМ УРОВНЕ

Любовь Юрьевна Жигулева; Мугутдинович Абдулкадыров Кудрат

doi:10.21638/11701/spbu11.2016.311.

Authors

Любовь Юрьевна Жигулева Russian Research Institute of Hematology and Transfusiology, 16, 2nd Sovietskaya ulitsa, Saint Petersburg, 191024, Russian Federation
Мугутдинович Абдулкадыров Кудрат Russian Research Institute of Hematology and Transfusiology, 16, 2nd Sovietskaya ulitsa, Saint Petersburg, 191024, Russian Federation

DOI:

https://doi.org/10.21638/11701/spbu11.2016.311.

Abstract

This article presents an analysis of changing parameters of cumulative 5-year survival, corrected and relative survival of patients with various hematological malignancies in Saint-Petersburg with the population divided in relation to sex, age, and the time of diagnosis (for 1996–1999, 2000–2003 and 2004–2007). The study was conducted according to the database of the Population Cancer Register (PCR) of Saint-Petersburg. Parameters were calculated with the actuarial method using the PCR software complex. Positive survival changes were noted in patients with Hodgkins lymphoma, multiple myeloma, acute lymphoblastic leukemia (<18 years-old group (y. o.)), chronic lymphoid leukemia, chronic myeloid leukemia (<60 y. o.); negative changes were observed in acute myeloid leukemia, acute lymphoblastic leukemia (≥18 y. o.), chronic myeloid leukemia (≥60 y. o.). Male survival was lower in the majority of hematological malignancies compared to female survival. Positive survival changes indicate the efficacy of the programmed treatment of hematological malignancies. The most striking increase of patient survival was noted for those diagnosed in years 2004–2007, which may be explained by the use of highly efficient target drugs of the latest generations. Patients’ age had the most significant impact on survival parameters. Refs 8. Tables 8.

Keywords:

survival, hematological malignancies, population level

Downloads

Download data is not yet available.

References

Литература

Абдулкадыров К. М., Волошин С. В., Шмидт А. В. и др. Эффективность бортезомиба при лечении больных рецидивирующей и рефрактерной множественной миеломой (анализ российских данных исследования (EVOBS) // Гематология и трансфузиология. 2012. Т. 57, № 3. С. 22–25.

Семочкин С. В. Помалидомид в лечении рецидивов рефрактерных форм множественной миеломы // Клиническая онкогематология. 2015. Т. 8, № 4. С. 379–389.

Абдулкадыров К. М., Шуваев В. А., Мартынкевич И. С. и др. Хронический миелолейкоз: многолетний опыт таргетной терапии // Клиническая онкогематология. 2016. Т. 9, № 1. С. 54–60.

Zangari M., Tricot G., Polavaram L. et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone // JCO. 2010. Vol. 28, Nо 1. P. 132–135.

Gay F., Hayman S. R., Lacy M. Q. et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients // Blood. 2010. Vol. 115, Nо 7. P. 1343–1350.

Мерабишвили В. М. Онкологическая статистика (традиционные методы, новые информационные технологии): руководство для врачей. СПб.: Коста, 2011. Ч. II. 248 с.

Петрова Г. В., Грецова О. П., Харченко Н. В. Методы расчета показателей выживаемости // Злокачественные новообразования в России в 2003 году (заболеваемость и смертность) / под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. М., 2005. С. 246–254.

Berrino F., De Angelis R., Sant M. et al. Eurocare Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results the Eurocare-4 study // Lancet Oncol. 2007. Vol. 8, nо. 9, pp. 773–783.

References

Abdulkadyrov K. M., Voloshin S. V., Shmidt A. V. et al. Effektivnost’ bortezomiba pri lechenii bol’nykh retsidiviruiushchei i refrakternoi mnozhestvennoi mielomoi (analiz rossiiskikh dannykh issledovaniia (EVOBS)Эффективность бортезомиба при лечении больных рецидивирующей и рефрактерной множественной миеломой (анализ российских данных исследования (EVOBS) [Efficacy of Bortezomib in the treatment of patients with relapsing and refractory multiple myeloma (analysis of Russian data from the EVOBS study)]. Hematology and transfusion medicine, 2012, vol. 57, no. 3, pp. 22–25. (In Russian)

Semochkin S. V. Pomalidomid v lechenii retsidivov refrakternykh form mnozhestvennoi mielomyПомалидомид в лечении рецидивов рефрактерных форм множественной миеломы [Pomalidomide in the treatment of relapsing refractory forms of multiple myeloma]. Clinical oncohematology,2015, vol. 8, no. 4, pp. 379–389. (In Russian)

Abdulkadyrov K. M., Shuvaev V. A., Martynkevich I. S. et al. Khronicheskii mieloleikoz: mnogoletnii opyt targetnoi terapiiХронический миелолейкоз: многолетний опыт таргетной терапии [Chronic myeloid leukemia: long-term experience of target treatment]. Clinical oncohematology, 2016, vol. 9, no. 1, pp. 54–60. (In Russian)

Zangari M., Tricot G., Polavaram L. et al. Survival effect of venous thromboembolism in patients with multiple myeloma treated with lenalidomide and high-dose dexamethasone. JCO, 2010, vol. 28, nо. 1, pp. 132–135.

Gay F., Hayman S. R., Lacy M. Q. et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma: a comparative analysis of 411 patients. Blood, 2010,vol. 115, nо. 7, pp. 1343–1350.

Merabishvili V. M. Onkologicheskaia statistika (traditsionnye metody, novye informatsionnye tekhnologii): rukovodstvo dlia vrachei [Oncological statistics (traditional methods, new information technologies).Guadelines for physicians]. St. Petersburg, Kosta Publ., 2011. Part II. 248 p. (In Russian)

Petrova G. V., Gretsova O. P., Kharchenko N. V. [Methods of calculating survival parameters].Zlokachestvennye novoobrazovaniia v Rossii v 2003 godu (zabolevaemost’ i smertnost’) [Malignancies in Russia in year 2003 (morbidity and mortality)].Eds. V. I. Chissov, V. V. Starinsky, G. V. Petrova. Moscow, 2005, pp. 246–254. (In Russian)

Berrino F., De Angelis R., Sant M. et al. Eurocare Working group. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results the Eurocare-4 study. Lancet Oncol.,2007, vol. 8, nо. 9, pp. 773–783.